| scholarly article | Q13442814 |
| P50 | author | Richard Schäfer | Q42722813 |
| P2093 | author name string | Christoph H Gleiter | |
| William H Frey | |||
| Andreas von Ameln-Mayerhofer | |||
| Barbara Proksch | |||
| Gayane H Buniatian | |||
| Lusine Danielyan | |||
| Miriam Ayturan | |||
| Marine Buadze | |||
| Julia Geisler | |||
| Stephan Verleysdonk | |||
| Tim Klopfer | |||
| Ute Burkhardt | |||
| P433 | issue | 6 | |
| P304 | page(s) | 315-324 | |
| P577 | publication date | 2009-03-25 | |
| P1433 | published in | European Journal of Cell Biology | Q1524072 |
| P1476 | title | Intranasal delivery of cells to the brain | |
| P478 | volume | 88 |
| Q42076693 | Air-assisted intranasal instillation enhances adenoviral delivery to the olfactory epithelium and respiratory tract |
| Q26778149 | Alzheimer's Disease: Mechanism and Approach to Cell Therapy |
| Q34961530 | Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles |
| Q38028845 | Brain dendritic cells: biology and pathology. |
| Q48554148 | Bystander effect on brain tissue of mesoangioblasts producing neurotrophins |
| Q36112863 | CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. |
| Q33361553 | Can oral infection be a risk factor for Alzheimer's disease? |
| Q27025754 | Cell based therapies for ischemic stroke: from basic science to bedside |
| Q38219641 | Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers. |
| Q40117969 | Comorbidity of periodontal disease: two sides of the same coin? An introduction for the clinician |
| Q52591432 | Delayed and repeated intranasal delivery of bone marrow stromal cells increases regeneration and functional recovery after ischemic stroke in mice. |
| Q34432396 | Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice |
| Q47893291 | Demonstration of Direct Nose-to-Brain Transport of Unbound HIV-1 Replication Inhibitor DB213 Via Intranasal Administration by Pharmacokinetic Modeling |
| Q90981389 | Demonstration of Infectious Transgression Through the Skull Base Occurring 9 Years After Pituitary Adenoma Resection |
| Q41953178 | Detection of cyanotoxins, β-N-methylamino-L-alanine and microcystins, from a lake surrounded by cases of amyotrophic lateral sclerosis. |
| Q35608828 | Detection of intranasally delivered bone marrow-derived mesenchymal stromal cells in the lesioned mouse brain: a cautionary report |
| Q34339313 | Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting |
| Q48489678 | Drug transport into the central nervous system: using newer findings about the blood-brain barriers |
| Q35529165 | Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans |
| Q37731533 | Erythropoietin in stroke: quo vadis |
| Q31140077 | Estradiol prevents olfactory dysfunction induced by A-β 25-35 injection in hippocampus |
| Q34076957 | Expression and regulation in the brain of the chemokine CCL27 gene locus |
| Q48534103 | Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease |
| Q35675598 | Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease |
| Q47405412 | Getting Closer to an Effective Intervention of Ischemic Stroke: The Big Promise of Stem Cell |
| Q64926356 | Human Mesenchymal Stem Cells Prevent Neurological Complications of Radiotherapy. |
| Q42368133 | Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal? |
| Q92816537 | Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease |
| Q37304992 | Intranasal Delivery of Neural Stem Cells: A CNS-specific, Non-invasive Cell-based Therapy for Experimental Autoimmune Encephalomyelitis |
| Q48766381 | Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model |
| Q34284391 | Intranasal administration of aTf protects and repairs the neonatal white matter after a cerebral hypoxic-ischemic event |
| Q38104559 | Intranasal administration of oxytocin: behavioral and clinical effects, a review |
| Q42228954 | Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. |
| Q50862423 | Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice. |
| Q58551682 | Intranasal breast milk for premature infants with severe intraventricular hemorrhage-an observation |
| Q87716594 | Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis |
| Q35876200 | Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. |
| Q48346065 | Intranasal delivery of bone marrow mesenchymal stem cells improved neurovascular regeneration and rescued neuropsychiatric deficits after neonatal stroke in rats |
| Q38303586 | Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease |
| Q53608103 | Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis. |
| Q38648551 | Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors |
| Q36861449 | Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma |
| Q48117495 | Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies. |
| Q38342080 | Intranasal delivery of stem cells as therapy for central nervous system disease |
| Q37854671 | Intranasal delivery of stem cells to the brain |
| Q37880893 | Intranasal delivery of therapeutic proteins for neurological diseases. |
| Q38553213 | Intranasal delivery: circumventing the iron curtain to treat neurological disorders |
| Q100523325 | Intranasal mesenchymal stem cell therapy to boost myelination after encephalopathy of prematurity |
| Q44115717 | Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice |
| Q64932512 | Intranasal rifampicin for Alzheimer's disease prevention. |
| Q37142166 | Intranasal treatment of central nervous system dysfunction in humans |
| Q47983763 | Intranasally Delivered Wnt3a Improves Functional Recovery after Traumatic Brain Injury by Modulating Autophagic, Apoptotic and Regenerative Pathways in the Mouse Brain |
| Q64057516 | Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma |
| Q34261645 | Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration |
| Q50229788 | Mesenchymal stem cell therapy for the streptozotocin-induced neurodegeneration in rats. |
| Q26999783 | Mesenchymal stem cell transplantation in multiple sclerosis |
| Q37995016 | Mesenchymal stem cells as a treatment for neonatal ischemic brain damage |
| Q34473474 | Mesenchymal stem cells for the treatment of neurodegenerative disease. |
| Q42030016 | Mesenchymal stem cells for trinucleotide repeat disorders |
| Q35847142 | Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease |
| Q48525432 | Methods of Drug Delivery in Neurotrauma |
| Q47228668 | Migratory potential of transplanted glial progenitors as critical factor for successful translation of glia replacement therapy: The gap between mice and men. |
| Q47280331 | Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease |
| Q50571934 | NF-κB Signaling is Involved in the Effects of Intranasally Engrafted Human Neural Stem Cells on Neurofunctional Improvements in Neonatal Rat Hypoxic-Ischemic Encephalopathy. |
| Q42262319 | Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting |
| Q26775932 | Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges |
| Q38353261 | Opportunities and challenges: stem cell-based therapy for the treatment of ischemic stroke. |
| Q41836711 | Patient-specific pluripotent stem cells in neurological diseases |
| Q64070071 | Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma |
| Q90197287 | Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats |
| Q48788828 | Preeclampsia enhances neuroglial marker expression in umbilical cord Wharton's jelly-derived mesenchymal stem cells |
| Q48096160 | Promoting neuroregeneration after perinatal arterial ischemic stroke: Neurotrophic factors and mesenchymal stem cells |
| Q64103670 | Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders |
| Q38364826 | Remyelination in multiple sclerosis: what do we know and where are we going? |
| Q48162399 | Repair of neonatal brain injury: bringing stem cell-based therapy into clinical practice |
| Q28079830 | Review of Preclinical and Clinical Studies of Bone Marrow-Derived Cell Therapies for Intracerebral Hemorrhage |
| Q55091426 | Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses. |
| Q35073816 | Spatial distribution of insulin-like growth factor binding protein-2 following hypoxic-ischemic injury |
| Q54015446 | Stem Cell Therapy and Administration Routes After Stroke. |
| Q37967608 | Stem cell therapy for neonatal brain injury: perspectives and challenges |
| Q35501361 | Stem cell therapy in intracerebral hemorrhage rat model |
| Q38742380 | Stem cell transplantation therapy for multifaceted therapeutic benefits after stroke |
| Q59131854 | Stem cell-secreted 14,15- epoxyeicosatrienoic acid rescues cholesterol homeostasis and autophagic flux in Niemann-Pick-type C disease |
| Q64260095 | The Potential of Stem Cell Therapy to Repair White Matter Injury in Preterm Infants: Lessons Learned From Experimental Models |
| Q55610792 | The Route by Which Intranasally Delivered Stem Cells Enter the Central Nervous System. |
| Q37587220 | The Skin-Brain Connection Hypothesis, Bringing Together CCL27-Mediated T-Cell Activation in the Skin and Neural Cell Damage in the Adult Brain |
| Q34706705 | The effect of osteopontin and osteopontin-derived peptides on preterm brain injury |
| Q38081017 | The endogenous regenerative capacity of the damaged newborn brain: boosting neurogenesis with mesenchymal stem cell treatment. |
| Q87290248 | The involvement of CXCL11 in bone marrow-derived mesenchymal stem cell migration through human brain microvascular endothelial cells |
| Q38236698 | The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview |
| Q91013999 | The neurorestorative effect of human amniotic fluid stem cells on the chronic phase of neonatal hypoxic-ischemic encephalopathy in mice |
| Q21560838 | The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS |
| Q61806270 | The spleen may be an important target of stem cell therapy for stroke |
| Q41876349 | Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage |
| Q48022024 | Tissue-specific immunopathology during malaria infection |
| Q26825854 | Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury |
| Q37997539 | Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke. |
| Q37672609 | UDP-glucuronosyltransferases (UGTs) in neuro-olfactory tissues: expression, regulation, and function. |
| Q37585010 | siRNA Treatment: "A Sword-in-the-Stone" for Acute Brain Injuries |
Search more.